US 12,403,178 B2
Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)
Patrick Soon-Shiong, Culver City, CA (US); Hans G Klingemann, Culver City, CA (US); Laurent H Boissel, Culver City, CA (US); Himani Chinnapen, Culver City, CA (US); and Abhijit Dandapat, Culver City, CA (US)
Assigned to ImmunityBio, Inc., Culver City, CA (US)
Filed by ImmunityBio, Inc., Culver City, CA (US)
Filed on Sep. 8, 2023, as Appl. No. 18/463,907.
Application 18/463,907 is a continuation of application No. 16/966,868, granted, now 11,813,292, previously published as PCT/US2019/021647, filed on Mar. 11, 2019.
Claims priority of provisional application 62/641,915, filed on Mar. 12, 2018.
Prior Publication US 2024/0016849 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01)
CPC A61K 38/1774 (2013.01) [A61K 39/4613 (2023.05); A61K 39/4631 (2023.05); A61K 39/4644 (2023.05); A61K 39/464411 (2023.05); A61K 2239/48 (2023.05)] 22 Claims
 
1. A composition comprising a genetically modified T cell or Natural Killer (NK) cell, wherein the modified T cell or NK cell expresses a chimeric antigen receptor (CAR) that specifically targets a tumor-associated antigen, wherein the CAR comprises 1) a first amino acid sequence comprising an antigen binding domain and 2) a second amino acid sequence comprising a CD8 hinge domain, a CD28 transmembrane domain, and an FcεRIγ signaling domain, wherein the second amino acid sequence has at least 95% sequence identity to amino acids 268-401 of SEQ ID NO: 16.
 
12. A method for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both, in a subject in need thereof, the method comprising: administering to the subject, intravenously or by injection, 1) a therapeutically effective amount of a genetically modified NK cell comprising a) a chimeric antigen receptor (CAR) that specifically binds CD33, wherein the CAR comprises a first amino acid sequence comprising a CD33 binding domain and a second amino acid sequence comprising a CD8 hinge domain, a CD28 transmembrane domain, and an FcεRIγ signaling domain, wherein the second amino acid sequence has at least 95% sequence identity to amino acids 268-401 of SEQ ID NO: 16, and b) a CD16 receptor; and 2) a therapeutically effective amount of an antibody.
 
17. A composition comprising 1) an effective amount of a genetically modified NK cell comprising a) a chimeric antigen receptor (CAR) that specifically binds CD33, wherein the CAR comprises a first amino acid sequence comprising a CD33 binding domain and a second amino acid sequence comprising a CD8 hinge domain, a CD28 transmembrane domain, and an FcεRIγ signaling domain, wherein the second amino acid sequence has at least 95% sequence identity to amino acids 268-401 of SEQ ID NO: 16, and b) a CD16 receptor; and 2) an effective amount of an antibody.